Praxis’ vormatrigine reduced seizures by 56.3%, an effect size that, according to analysts at Truist Securities, exceeds that ...

While the deaths occurred in patients who had been treated with Agios’ anemia treatment Pyrukynd, the biotech insisted in an ...

In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

From innovation in manufacturing to more-flexible regulation and better communication with payers, much needs to happen to ...

The primary focus in scaling up production should first be the adoption of lean manufacturing principles used in virtually ...

The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of ...

Josh Ludwig is global commercial director at ScaleReady, where he leads a team of scientists that drives new business through ...